Early calcineurin-inhibitor to belatacept conversion in steroid-free kidney transplant recipients

BACKGROUND: Belatacept (Bela) was developed to reduce nephrotoxicity and cardiovascular risk that are associated with the chronic use of Calcineurin inhibitors (CNIs) in kidney transplant recipients. The use of Bela with early steroid withdrawal (ESW) and simultaneous CNI avoidance has not been form...

Descripción completa

Detalles Bibliográficos
Autores principales: Tawhari, Ibrahim, Hallak, Patrick, Bin, Sofia, Yamani, Fatmah, Safar-Boueri, Maria, Irshad, Aazib, Leventhal, Joseph, Ansari, Mohammed Javeed, Cravedi, Paolo, Gallon, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806416/
https://www.ncbi.nlm.nih.gov/pubmed/36601111
http://dx.doi.org/10.3389/fimmu.2022.1096881

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9806416/
https://www.ncbi.nlm.nih.gov/pubmed/36601111
http://dx.doi.org/10.3389/fimmu.2022.1096881

Ejemplares similares